Please provide your email address to receive an email when new articles are posted on . Patients with palmoplantar plaque-type psoriasis had significantly improved signs and symptoms of disease when ...

The IL-23 inhibitor risankizumab proved to be safe and efficacious after 52 weeks of treatment in patients with palmoplantar psoriasis. Results from the randomized phase 3b study appear in the Journal ...

If you’ve struggled with itchy, irritated skin, you’ve probably sought out various creams, lotions or ointments to treat it. But if you feel like you’ve tried everything and still suffer from dry and ...

Please provide your email address to receive an email when new articles are posted on . Chovatiya, clinical associate professor at Chicago Medical School at Rosalind Franklin University and assistant ...

Pediatric patients with psoriasis exhibited significant improvements in self-reported outcomes and objective measures of complete skin clearance when treated with ixekizumab vs placebo, with no new ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar ...

Two-year follow-up data from an international, multicenter, randomized trial of ixekizumab in pediatric patients with moderate to severe psoriasis demonstrate prolonged efficacy and no new safety ...

MoonLake Immunotherapeutics has announced the initiation of new trials for sonelokimab, an investigational Nanobody® aimed at treating inflammatory diseases. The Phase 3 VELA-TEEN trial will evaluate ...

Assessing disease severity in younger patients remains complex because adult scoring tools may underestimate the disease ...

You’ve probably heard of psoriasis—the chronic inflammatory condition that can cause itchy, scaly patches on your skin. Less well-known is a rare form of the disease called pustular psoriasis, which ...